Rick Maffei

[OncoTargets and Therapy] Researchers outline promising findings for the use of polatuzumab vedotin for patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma.

[OncoTargets and Therapy] While multimodal treatment can be curative in select cases of r/r pediatric sarcoma, treatment refractoriness remains a tremendous hurdle for clinicians.

1.0 AMA PRA Category 1 Credit(s)^TM
1.0 AANP Contact Hour(s) which includes 1.0 pharmacology hours

[Cancer Management and Research] A retrospective review of 30 patients who underwent resection of spinal tumor caused by metastatic SCLC demonstrated that surgery was critical to improving patients QOL and performance status.

[Cancer Management and Research] Researchers sought to quantify the effect of the measures taken to reduce transmission of the coronavirus on diagnosis and treatment of nasopharyngeal cancer.

Researchers evaluated the prevalence, level, and impact on QOL of patient-reported urinary incontinence at baseline and after 3 months of systemic therapy.

[Cancer Management and Research] Researchers sought to determine if apatinib-related hypertension was a predictor of drug efficacy in patients with advanced HCC.

In this patient case, significant neurological adverse effects associated with nelarabine were noted at 30 days following initiation of therapy.

[Cancer Management and Research] This review discusses advances in minimal residual disease monitoring in patients with CML, including its role in defining treatment response, choosing the best therapeutic strategy, and selecting patients who may be eligible for TKI discontinuation.

[OncoTargets and Therapy] PLELC is a rare and distinct subtype of NSCLC associated with Epstein-Barr virus infection. Usually detected at early stage, prognosis is better for patients with PLELC than for those with other subtypes of NSCLC. This review discusses etiology, diagnosis, and treatment of the disease.